Prostate cancer starts in the prostate, a small gland located just below the bladder in men. This gland is essential for reproductive function, as it produces the seminal fluid that nourishes and transports sperm. Prostate cancer develops when cells in the gland begin to grow uncontrollably. If not caught early, the cancer can spread beyond the prostate to nearby tissues and organs, eventually reaching bones or lymph nodes, becoming metastatic and more challenging to treat.
The aggressiveness of prostate cancer is typically measured using a Gleason score, which ranges from 6 to 10. This scoring system assesses how abnormal the cancer cells appear under a microscope compared to healthy cells. Lower scores, like 6 or 7, suggest less aggressive cancer with slower growth. Higher scores of 8, 9, or 10 indicate aggressive cancers that are likely to grow quickly and spread. In Biden's case, his Gleason score was reported as 9, marking the cancer as particularly aggressive and fast-developing.
Prostate cancer often shows no symptoms in its early stages. As the tumor grows, however, it may lead to noticeable issues such as difficulty urinating, frequent urination at night, pain or burning during urination, and blood in the urine or semen. In advanced stages, symptoms may extend to back or bone pain, fatigue, erectile dysfunction, urinary incontinence, and weakness in the legs or hips. Unfortunately, by the time these symptoms become apparent, the cancer may have already progressed significantly.
Though the exact cause of prostate cancer remains unknown, several risk factors have been identified. Age is the most significant—risk increases considerably in men over 50. Family history also plays a key role; those with close relatives who have had prostate cancer are more likely to be diagnosed themselves. Additionally, racial background is relevant, with higher incidence and mortality rates reported among African American men. Lifestyle factors, including diet and obesity, may also contribute to increased risk.
Prostate cancer is most commonly detected through blood tests that measure levels of prostate-specific antigen (PSA), a protein produced by the prostate. Elevated PSA levels can signal the presence of cancer, though not always conclusively. Doctors may also perform a digital rectal exam (DRE) to physically check the prostate for abnormalities. If screening tests indicate potential cancer, further diagnostic tools are used, such as MRI scans, transrectal ultrasounds, and prostate biopsies to analyze tissue samples. Advanced imaging tests like bone scans and CT scans may be used in more severe or suspected metastatic cases.
Treatment for prostate cancer depends on how advanced it is and the individual health needs of the patient. For early-stage, slow-growing cancers, a watchful waiting or active surveillance approach may be sufficient. However, more aggressive cancers like the one diagnosed in Biden typically require immediate intervention. Treatments may include surgery to remove the prostate gland (prostatectomy), radiation therapy, and chemotherapy. Some patients benefit from newer targeted therapies, such as those that focus on prostate-specific membrane antigens (PSMA), or from immunotherapy designed to help the body’s immune system attack cancer cells more effectively.
When prostate cancer becomes metastatic, treatment becomes more complicated. The primary focus shifts to slowing the spread and managing symptoms, as completely eliminating the disease becomes difficult. Medications, hormonal therapies, and palliative care options help improve quality of life and extend survival time. Nonetheless, treatment plans are often complex and need to be tailored to each patient’s specific situation.
Survival rates for prostate cancer vary significantly depending on the stage at diagnosis and the patient's age and overall health. When detected early and localized, the five-year survival rate is around 98% for men under 65. For older individuals, especially those over 80, the survival rate tends to be lower, at about 85%. However, if the cancer has metastasized to distant parts of the body, five-year survival rates fall to between 30% and 40%. These statistics underscore the importance of early detection and timely medical intervention.
Prostate cancer is extremely common. Current estimates suggest that one in eight men will be diagnosed with the disease during their lifetime. In recent years, the number of reported cases has increased, with projections indicating over 313,000 new diagnoses expected in 2025 alone. While this rise can be concerning, it is partially attributed to better awareness and improvements in screening practices, which allow doctors to catch cancers earlier. Presently, more than 3.3 million men in the United States alone are living with a history of prostate cancer, many of whom are in remission or managing the disease effectively.
The announcement of former President Joe Biden’s diagnosis serves as a powerful reminder of the seriousness of prostate cancer and the critical need for continued education, early screening, and access to advanced treatments. While aggressive prostate cancer presents serious health challenges, modern medicine offers a range of tools that can significantly improve outcomes when the disease is caught and treated promptly. Staying informed and proactive about prostate health remains key to improving long-term survival and quality of life.
